Goldman Sachs
TSHA icon

Goldman Sachs’s Taysha Gene Therapies TSHA Stock Holding History

Goldman Sachs’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155M Buy
22,713,118
+343,473
+2% +$2.03M 0.01% 913
2026
Q1 		$100M Buy
22,369,645
+8,676,906
+63% +$40.3M 0.01% 1025
2025
Q4 		$75.3M Buy
13,692,739
+309,031
+2% +$1.5M 0.01% 1189
2025
Q3 		$43.8M Buy
13,383,708
+796,008
+6% +$2.25M 0.01% 1524
2025
Q2 		$29.1M Buy
12,587,700
+12,228,693
+3,406% +$26.6M ﹤0.01% 1785
2025
Q1 		$499K Sell
359,007
-608,137
-63% -$1.02M ﹤0.01% 5183
2024
Q4 		$1.67M Sell
967,144
-238,527
-20% -$495K ﹤0.01% 4444
2024
Q3 		$2.42M Buy
1,205,671
+178,653
+17% +$392K ﹤0.01% 3987
2024
Q2 		$2.3M Sell
1,027,018
-31,944
-3% -$93K ﹤0.01% 3817
2024
Q1 		$3.04M Buy
1,058,962
+975,488
+1,169% +$2.03M ﹤0.01% 3531
2023
Q4 		$148K Buy
+83,474
New +$166K ﹤0.01% 5227
2023
Q1 		– Sell
-12,127
Closed -$27.4K – 6234
2022
Q4 		$27.4K Sell
12,127
-31,356
-72% -$63.5K ﹤0.01% 5672
2022
Q3 		$84K Sell
43,483
-25,796
-37% -$93.6K ﹤0.01% 5727
2022
Q2 		$258K Sell
69,279
-19,760
-22% -$78.4K ﹤0.01% 5504
2022
Q1 		$580K Buy
89,039
+35,991
+68% +$269K ﹤0.01% 5218
2021
Q4 		$618K Buy
53,048
+40,949
+338% +$618K ﹤0.01% 5228
2021
Q3 		$225K Buy
+12,099
New +$230K ﹤0.01% 5670
2021
Q1 		– Sell
-14,763
Closed -$392K – 6359
2020
Q4 		$392K Sell
14,763
-63,862
-81% -$1.38M ﹤0.01% 4753
2020
Q3 		$1.76M Buy
+78,625
New +$1.85M ﹤0.01% 3653

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Goldman Sachs's TSHA Position: Q2 2026 in Review

Goldman Sachs increased its Taysha Gene Therapies (TSHA) stake by 1.5% in Q2 2026, buying an estimated $2.03M and bringing the position to 22,713,118 shares worth $155M. The position accounts for 0.01% of the portfolio, ranked #913.

Goldman Sachs first reported a position in TSHA in Q3 2020 and has held it in 19 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Goldman Sachs held 22,713,118 shares of Taysha Gene Therapies worth $155M as of Q2 2026.
  • Goldman Sachs bought 343,473 Taysha Gene Therapies shares in Q2 2026, an estimated $2.03M.
  • Taysha Gene Therapies made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #913 holding.
  • Goldman Sachs first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 19 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.